The validity of surrogate markers in rheumatic disease. by Emery, P, Luqmani, R

Disease-modifying antirheumatic drugs in rheumatoid arthritis: current concepts. by Emery, P, Luqmani, R, Gordon, C

COST-EFFECTIVENESS OF CERTOLIZUMAB PEGOL PLUS METHOTREXATE OR AS MONOTHERAPY FOR THE TREATMENT OF ACTIVE RHEUMATOID ARTHRITIS IN THE UNITED KINGDOM by Purcaru, O, Taylor, P, Emery, P, Palmer, S

Nonsteroidal anti-inflammatory drugs, gastroprotection, and benefit-risk. by Moore, R, Derry, S, Simon, L, Emery, P

Does treat to target or achieving remission improve radiographic outcome in psa? by Coates, L, Hensor, E, Emery, P, Conaghan, P, Helliwell, P

The dynamics of response as measured by multiple composite outcome tools in the TIght COntrol of inflammation in early Psoriatic Arthritis (TICOPA) trial. by Coates, L, Mahmood, F, Emery, P, Conaghan, P, Helliwell, P

Inner ear deafness in Wegener's granulomatosis. by Luqmani, R, Jubb, R, Emery, P, Reid, A, Adu, D

THE HLA CLASS II ASSOCIATIONS OF RHEUMATOID-ARTHRITIS CONFER SEVERITY NOT SUSCEPTIBILITY by Gough, A, Faint, J, Wordsworth, P, Salmon, M, Emery, P

Cyclophosphamide and systemic vasculitis. by Luqmani, R, Moots, R, Emery, P, Bacon, P, Adu, D

Two cases of 'Wegener's tuberculosis'. by Gordon, C, Luqmani, R, Fields, P, Howie, A, Emery, P

Systemic cytokine measurements: their role in monitoring the response to therapy in patients with rheumatoid arthritis. by Luqmani, R, Sheeran, T, Robinson, M, Richardson, K, Winkles, J, Emery, P

Posterior scleritis--an unusual manifestation of Cogan's syndrome. by Shah, P, Luqmani, R, Murray, P, Honan, W, Corridan, P, Emery, P

The association of HLA DR beta alleles with self-limiting and persistent forms of early symmetrical polyarthritis. by Salmon, M, Wordsworth, P, Emery, P, Tunn, E, Bacon, P, Bell, J

What should be the primary target of ‘treat to target’ in PsA? by Coates, L, Lubrano, E, Perrotta, F, Emery, P, Conaghan, P, Helliwell, P

Long-term follow-up of patients in the TIght COntrol of inflammation in early Psoriatic Arthritis (TICOPA) trial by Coates, L, Mahmood, F, Freeston, J, Emery, P, Conaghan, PG, Helliwell, PS

What should be the primary target of "treat to target" in psoriatic arthritis? by Coates, LC, Lubrano, E, Perrotta, FM, Emery, P, Conaghan, PG, Helliwell, PS

Separation and identification of rat skeletal muscle proteins using two-dimensional gel electrophoresis and mass spectrometry. by Yan, J, Harry, R, Wait, R, Welson, S, Emery, P, Preedy, V, Dunn, M

Combination therapy with a TNF antagonist and a CD4 monoclonal antibody in rheumatoid arthritis. A pilot study. by Morgan, A, Hale, G, Rebello, P, Richards, S, Waldmann, H, Emery, P, Isaacs, J

Treat-to-target in psoriatic arthritis—cost-effective in the biosimilar era by Coates, L, O’Dwyer, J, Meads, D, Emery, P, Conaghan, PG, Helliwell, P

Genetically determined factors as predictors of radiological change in patients with early symmetrical arthritis. by Emery, P, Salmon, M, Bradley, H, Wordsworth, B, Tunn, E, Bacon, P, Waring, R